In an unexpected turn of events, 20 individuals in Japan have tragically lost their lives after taking a Kissei treatment drug. While details remain sparse, the authorities are diving deeply into an urgent investigation on a nationwide scale. The motive behind the issue is aimed at probing if the drug misuse or a latent flaw is the cause of concern. The public health field, shaken by the incident, calls for immense scrutiny of the drug's safety profile and manufacturers' regulatory compliance.

The crisis holds a profound impact on Japan, a nation renowned for its stringent drug regulations and top-tier overall health status. This incident, causing considerable trepidation, brings the country's pharmaceuticals, regulations, and public health system into focus. Public sentiment is heavily geared towards seeking accountability and assurance of safety of health treatments moving forward.

Issues around drug safety and related fatalities are dealt with seriously in both the EU and the US. Rigorous testing and regulatory oversight are provided before drugs are approved. However, despite the rigorous process, instances of drug-related adverse effects still occur occasionally. The EU often sees more cautionary and preventive measures to avoid such instances, while the US typically has stronger punitive measures and more class-action litigation for pharmaceutical companies at fault.